Douglas Thamm

Professor, Medical Oncology | Director of Clinical Research, Flint Animal Cancer Center Clinical Sciences

ACC216 VTH

970-297-4075

                    stdClass Object
(
    [AddressPrivacy] => 1
    [BusinessAddress1] => Veterinary Teaching Hospital - 300 W Drake Rd
    [BusinessAddress2] => Animal Cancer Center 216
    [BusinessCity] => Fort Collins
    [BusinessPostalCode] => 80523
    [BusinessState] => CO
    [CSUId] => 0
    [DepartmentGroup] => Clinical Sciences Department
    [DirectoryPrivacy] => 
    [EName] => dthamm
    [EmailAddress] => Doug.Thamm@ColoState.EDU
    [EmailPrivacy] => 
    [EmployeeCategory] => Faculty
    [EmployeeTitle] => Professor, Medical Oncology | Director of Clinical Research, Flint Animal Cancer Center
    [EmployeeType] => Faculty
    [FirstName] => Douglas
    [GraduationYear] => 
    [HasMemberCV] => 
    [Id] => 1053
    [InternalTitle] => Medical Oncology Faculty
    [LastName] => Thamm
    [MemberContacts] => stdClass Object
        (
            [MemberContactResponse] => stdClass Object
                (
                    [ContactTypeDescription] => Office
                    [Id] => 656
                    [IsPrimary] => 1
                    [PhoneNumber] => 970-297-4075
                )

        )

    [MemberDirectoryProfile] => stdClass Object
        (
            [Id] => 545
            [ProfileMetaData] => 
            [ProfileText] => Dr. Thamm is the Barbara Cox Anthony Professor of Oncology. His research centers around the characterization of important therapeutic targets in human oncology in spontaneous tumors of animal species sharing the environment with man, e.g. canines and felines. Through the implementation of pharmacokinetically and pharamcodynamically intensive animal clinical trials, his laboratory seeks to provide meaningful translational information to inform and develop novel therapies with potential to impact the treatment human and animal cancers. His current work centers on tyrosine and serine/thronine kinase signaling, validation of biomarkers for novel therapeutics, targeted therapy to enhance chemosensitivity. His presence in the faculty of mentors adds depth to the cancer biology/therapeutic realm of the program.
        )

    [MiddleName] => H
    [NamePrivacy] => 
    [OfficeBldgName] => VTH
    [OfficeRoomName] => ACC216
    [OtherName] => Douglas
    [PhonePrivacy] => 1
    [StudentLevel] => 
    [Website] => 
)

                

About Douglas

Dr. Thamm is the Barbara Cox Anthony Professor of Oncology. His research centers around the characterization of important therapeutic targets in human oncology in spontaneous tumors of animal species sharing the environment with man, e.g. canines and felines. Through the implementation of pharmacokinetically and pharamcodynamically intensive animal clinical trials, his laboratory seeks to provide meaningful translational information to inform and develop novel therapies with potential to impact the treatment human and animal cancers. His current work centers on tyrosine and serine/thronine kinase signaling, validation of biomarkers for novel therapeutics, targeted therapy to enhance chemosensitivity. His presence in the faculty of mentors adds depth to the cancer biology/therapeutic realm of the program.

Education

VMD, University of Pennsylvania, 1995BA, UNiversity of Pennsylvania, 1990

Certifications

Clinical
DACVIM (Oncology)

Publications

Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). J Vet Intern Med. 13: 491-497, 1999.Thamm DH, Kurzman ID, MacEwen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Lipid-complexed intralesional cytokine / superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 52: 473-480, 2003.Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 11(13): 4827-4834, 2005.Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 68(6): 581-587, 2006.Ptitsyn A, Weil M, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics. 9 (Suppl 9): S8, 2008.Rebhun R, Charles B, Ehrhart EJ, Lana SE, Thamm DH. Prognostic and comparative analysis of survivin expression in untreated and relapsed canine lymphoma. J Vet Intern Med. 22(4): 989-995, 2008.*Vail DM, *Thamm DH, Reiser H, Ray AS, Wolfgang GHI, Babusis D, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. A novel prodrug (GS-9219) demonstrates activity against non-Hodgkin’s lymphoma: a pet dog model. Clin Cancer Res. 15(10): 3503-3510, 2009. * Equal effort reportedThamm DH, Huelsmeyer MK, Mitzey AM, Qurollo BA, Rose BJ, Kurzman ID. RT-PCR based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res 20(1): 35-42, 2010.Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ, Kraft SL, Gustafson DL, Vail DM. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase-I evaluation. Clin Cancer Res 16: 1498-1508, 2010.Sottnik JA, Duval DL, Ehrhart III EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis 27(3): 151-160, 2010.Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li J, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy. Proc Natl Acad Sci USA 107(29): 13075-13080, 2010.Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid / doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res 16(19): 4832-4842, 2010.Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor sodium valproate sensitizes canine and human osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 67(1): 83-92, 2011.Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor promotes the malignant phenotype in canine mammary carcinoma. Vet Comp Oncol 9(3): 196-206, 2011.Sottnik JL, Lori JC, Rose BJ, Thamm DH. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis 28(8): 865-875, 2011.Wittenburg LA, Ptitsyn A, Thamm DH. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem 113(3): 773-783, 2012.Shoeneman JK, Ehrhart III EJ, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res 72(1): 249-259, 2012.Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM. Mutagen sensitivity as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. PLoS ONE 8(7): e69192, 2013.Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia) in canine mast cell tumor. BMC Vet Res 10: 105, 2014.

Species Interest

Small Animal Exclusive/Predominant (including pet exotics)

                
stdClass Object ( [GetMemberByIdResult] => stdClass Object ( [AddressPrivacy] => 1 [BusinessAddress1] => Veterinary Teaching Hospital - 300 W Drake Rd [BusinessAddress2] => Animal Cancer Center 216 [BusinessCity] => Fort Collins [BusinessPostalCode] => 80523 [BusinessState] => CO [CSUId] => 0 [DepartmentGroup] => Clinical Sciences Department [DirectoryPrivacy] => [EName] => dthamm [EmailAddress] => Doug.Thamm@ColoState.EDU [EmailPrivacy] => [EmployeeCategory] => Faculty [EmployeeTitle] => Professor, Medical Oncology | Director of Clinical Research, Flint Animal Cancer Center [EmployeeType] => Faculty [FirstName] => Douglas [GraduationYear] => [HasMemberCV] => [Id] => 1053 [InternalTitle] => Medical Oncology Faculty [LastName] => Thamm [MemberContacts] => stdClass Object ( [MemberContactResponse] => stdClass Object ( [ContactTypeDescription] => Office [Id] => 656 [IsPrimary] => 1 [PhoneNumber] => 970-297-4075 ) ) [MemberDirectoryProfile] => stdClass Object ( [Id] => 545 [ProfileMetaData] => [ProfileText] => Dr. Thamm is the Barbara Cox Anthony Professor of Oncology. His research centers around the characterization of important therapeutic targets in human oncology in spontaneous tumors of animal species sharing the environment with man, e.g. canines and felines. Through the implementation of pharmacokinetically and pharamcodynamically intensive animal clinical trials, his laboratory seeks to provide meaningful translational information to inform and develop novel therapies with potential to impact the treatment human and animal cancers. His current work centers on tyrosine and serine/thronine kinase signaling, validation of biomarkers for novel therapeutics, targeted therapy to enhance chemosensitivity. His presence in the faculty of mentors adds depth to the cancer biology/therapeutic realm of the program. ) [MiddleName] => H [NamePrivacy] => [OfficeBldgName] => VTH [OfficeRoomName] => ACC216 [OtherName] => Douglas [PhonePrivacy] => 1 [StudentLevel] => [Website] => ) )
stdClass Object ( [GetDirectoryInfoByMemberIdResult] => stdClass Object ( [DirectoryInfoResponse] => Array ( [0] => stdClass Object ( [DirectoryDescription] => DACVIM (Oncology) [DirectoryHeader] => Clinical [DirectoryNotes] => [DirectoryType] => Certification [DirectoryYear] => ) [1] => stdClass Object ( [DirectoryDescription] => VMD [DirectoryHeader] => University of Pennsylvania [DirectoryNotes] => [DirectoryType] => Degree [DirectoryYear] => 1995 ) [2] => stdClass Object ( [DirectoryDescription] => BA [DirectoryHeader] => UNiversity of Pennsylvania [DirectoryNotes] => [DirectoryType] => Degree [DirectoryYear] => 1990 ) [3] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). J Vet Intern Med. 13: 491-497, 1999. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [4] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Kurzman ID, MacEwen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT. Lipid-complexed intralesional cytokine / superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 52: 473-480, 2003. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [5] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 11(13): 4827-4834, 2005. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [6] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 68(6): 581-587, 2006. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [7] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Ptitsyn A, Weil M, Thamm DH. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics. 9 (Suppl 9): S8, 2008. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [8] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Rebhun R, Charles B, Ehrhart EJ, Lana SE, Thamm DH. Prognostic and comparative analysis of survivin expression in untreated and relapsed canine lymphoma. J Vet Intern Med. 22(4): 989-995, 2008. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [9] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => *Vail DM, *Thamm DH, Reiser H, Ray AS, Wolfgang GHI, Babusis D, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. A novel prodrug (GS-9219) demonstrates activity against non-Hodgkin’s lymphoma: a pet dog model. Clin Cancer Res. 15(10): 3503-3510, 2009. * Equal effort reported [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [10] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo BA, Rose BJ, Kurzman ID. RT-PCR based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res 20(1): 35-42, 2010. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [11] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ, Kraft SL, Gustafson DL, Vail DM. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase-I evaluation. Clin Cancer Res 16: 1498-1508, 2010. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [12] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Sottnik JA, Duval DL, Ehrhart III EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis 27(3): 151-160, 2010. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [13] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li J, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy. Proc Natl Acad Sci USA 107(29): 13075-13080, 2010. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [14] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid / doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res 16(19): 4832-4842, 2010. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [15] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor sodium valproate sensitizes canine and human osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 67(1): 83-92, 2011. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [16] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor promotes the malignant phenotype in canine mammary carcinoma. Vet Comp Oncol 9(3): 196-206, 2011. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [17] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Sottnik JL, Lori JC, Rose BJ, Thamm DH. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis 28(8): 865-875, 2011. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [18] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Wittenburg LA, Ptitsyn A, Thamm DH. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem 113(3): 773-783, 2012. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [19] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Shoeneman JK, Ehrhart III EJ, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res 72(1): 249-259, 2012. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [20] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Thamm DH, Grunerud KK, Rose BJ, Vail DM, Bailey SM. Mutagen sensitivity as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. PLoS ONE 8(7): e69192, 2013. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [21] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Halsey CHC, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia) in canine mast cell tumor. BMC Vet Res 10: 105, 2014. [DirectoryNotes] => [DirectoryType] => Publication [DirectoryYear] => ) [22] => stdClass Object ( [DirectoryDescription] => [DirectoryHeader] => Small Animal Exclusive/Predominant (including pet exotics) [DirectoryNotes] => [DirectoryType] => Species Interest [DirectoryYear] => ) [23] => stdClass Object ( [DirectoryDescription] => http://www.ncbi.nlm.nih.gov/pubmed/?term=thamm+d [DirectoryHeader] => Dr. Thamm's PubMed page [DirectoryNotes] => [DirectoryType] => Link [DirectoryYear] => ) ) ) ) Array ( [0] => GetMembersBySearchNameResponse GetMembersBySearchName(GetMembersBySearchName $parameters) [1] => GetMembersBySearchNameAndGroupKeyResponse GetMembersBySearchNameAndGroupKey(GetMembersBySearchNameAndGroupKey $parameters) [2] => GetMembersByMemberNameResponse GetMembersByMemberName(GetMembersByMemberName $parameters) [3] => GetGroupsByMemberIdResponse GetGroupsByMemberId(GetGroupsByMemberId $parameters) [4] => GetMemberByIdResponse GetMemberById(GetMemberById $parameters) [5] => GetGroupByIdResponse GetGroupById(GetGroupById $parameters) [6] => GetGroupByGroupKeyResponse GetGroupByGroupKey(GetGroupByGroupKey $parameters) [7] => GetMemberPhotoByMemberIdResponse GetMemberPhotoByMemberId(GetMemberPhotoByMemberId $parameters) [8] => GetMemberContactsByMemberIdResponse GetMemberContactsByMemberId(GetMemberContactsByMemberId $parameters) [9] => GetDirectoryProfileByMemberIdResponse GetDirectoryProfileByMemberId(GetDirectoryProfileByMemberId $parameters) [10] => GetDirectoryInfoByMemberIdResponse GetDirectoryInfoByMemberId(GetDirectoryInfoByMemberId $parameters) [11] => GetMembersByGroupIdResponse GetMembersByGroupId(GetMembersByGroupId $parameters) [12] => GetMembersByGroupKeyResponse GetMembersByGroupKey(GetMembersByGroupKey $parameters) [13] => GetCVByMemberIdResponse GetCVByMemberId(GetCVByMemberId $parameters) [14] => GetMembersByEmployeeCategoryResponse GetMembersByEmployeeCategory(GetMembersByEmployeeCategory $parameters) [15] => GetMembersByEmployeeCategoriesResponse GetMembersByEmployeeCategories(GetMembersByEmployeeCategories $parameters) [16] => GetMembersByEmployeeCategoryAndGroupKeyResponse GetMembersByEmployeeCategoryAndGroupKey(GetMembersByEmployeeCategoryAndGroupKey $parameters) )
stdClass Object ( [GetMemberContactsByMemberIdResult] => stdClass Object ( [MemberContactResponse] => stdClass Object ( [ContactTypeDescription] => Office [Id] => 656 [IsPrimary] => 1 [PhoneNumber] => 970-297-4075 ) ) )